Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

FitBit and app aim to keep cancer surgery patients out of the hospital

NCT ID NCT03623464

Symptom relief Sponsor: Weill Medical College of Cornell University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether using a FitBit and a mobile app can help people recover at home after surgery for stomach, liver, colon, or other GI cancers. About 107 patients will either use the devices plus standard care, or standard care alone. The app tracks activity and symptoms, and alerts doctors if something seems wrong, with the goal of preventing hospital readmissions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
FitBit and mobile health application
What this could lead to
If it works, this could give doctors a simple way to monitor recovery at home and reduce the chance of patients needing to return to the hospital after surgery.
What could go wrong
This is a small, early-stage study with only 107 people, so results may not apply to everyone. The devices rely on patients having and using a smartphone, which could limit usefulness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

107 people

The number who actually took part.

Started

May 2017

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subject is 18 years or older 2. Subject speaks English 3. Subject owns a smart phone 4. Subject is scheduled to undergo surgery for a GI cancer (pancreatic, hepatic, gastric, small bowel, colon, or rectal cancers) Exclusion Criteria: 1. Physician deems the subject is unable to complete the study due to documented dementia 2. Subject is undergoing emergent surgery 3. Subject has sepsis from another source 4. Physician deems the subject is unable to complete the study due to documented alcohol and/or drug abuse

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colon cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

carcinoma of liver and intrahepatic biliary tract colon carcinoma colonic neoplasm gastric cancer gastric neoplasm liver cancer Liver Neoplasms malignant pancreatic neoplasm pancreatic neoplasm rectal cancer rectal neoplasm small intestine carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colon cancer Gastric cancer Hepatic cancer Pancreatic cancer Rectal cancer Small bowel cancer

Contacts and locations

Locations

  • Weill Cornell Medicine- New York Presbyterian

    New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.